News For Placebo


Taiho Oncology and Servier Present Data on LONSURF® (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI) - PRNewswire

Taiho Oncology and Servier Present Data on LONSURF® (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)  PRNewswire

PRINCETON, N.J., Jan. 17, 2019 /PRNewswire/ -- Taiho Oncology, Inc. and Servier announced today that the safety and efficacy in patients with gastrectomy ...

Google 1/17/2019 11:45:00 PM

Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ (levodopa inhalation powder) - Business Wire

Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ (levodopa inhalation powder)  Business Wire

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that The Lancet Neurology published results from SPAN℠-PD, the Phase 3 pivotal efficacy trial.

Google 1/17/2019 11:30:00 PM

Tafenoquine Can't Prove Non-Inferiority to Prevent Malaria Relapse - MedPage Today

Tafenoquine Can't Prove Non-Inferiority to Prevent Malaria Relapse  MedPage Today

Compared to primaquine, tafenoquine had a similar safety profile and acceptable efficacy for the radical cure of malaria, but non-inferiority for preventing relapse ...

Google 1/17/2019 11:00:00 PM

F.D.A. Panel Splits on Whether to Approve New Diabetes Drug - The New York Times

F.D.A. Panel Splits on Whether to Approve New Diabetes Drug  The New York Times

An advisory panel for the Food and Drug Administration split evenly on Thursday over whether the agency should approve the first oral medication to treat Type ...

Google 1/17/2019 10:54:38 PM

Seysara Now Available for Moderate-to-Severe Acne Vulgaris - Monthly Prescribing Reference

Seysara Now Available for Moderate-to-Severe Acne Vulgaris  Monthly Prescribing Reference

Almirall announced the availability of Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ...

Google 1/17/2019 7:35:10 PM

First clinical study shows mavoglurant improves eye gaze behavior in fragile X syndrome patients - Medical Xpress

First clinical study shows mavoglurant improves eye gaze behavior in fragile X syndrome patients  Medical Xpress

Researchers at Rush University Medical Center and the MIND Institute at UC Davis have found that mavoglurant, an experimental drug known as an mGluR5 ...

Google 1/17/2019 7:00:09 PM

Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC - OncLive

Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC  OncLive

Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small ...

Google 1/17/2019 6:58:31 PM

Spironolactone effective as HFpEF treatment regardless of kidney function, but safety less clear - Healio

Spironolactone effective as HFpEF treatment regardless of kidney function, but safety less clear  Healio

The efficacy of spironolactone in patients with HF with preserved ejection fraction was consistent across the range of kidney function, although adverse events ...

Google 1/17/2019 6:35:22 PM

 1 2 3 4 5  ...